Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12456031rdf:typepubmed:Citationlld:pubmed
pubmed-article:12456031lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:12456031lifeskim:mentionsumls-concept:C0038179lld:lifeskim
pubmed-article:12456031lifeskim:mentionsumls-concept:C0574032lld:lifeskim
pubmed-article:12456031lifeskim:mentionsumls-concept:C0700307lld:lifeskim
pubmed-article:12456031lifeskim:mentionsumls-concept:C1317973lld:lifeskim
pubmed-article:12456031lifeskim:mentionsumls-concept:C0428441lld:lifeskim
pubmed-article:12456031lifeskim:mentionsumls-concept:C0183683lld:lifeskim
pubmed-article:12456031lifeskim:mentionsumls-concept:C0344211lld:lifeskim
pubmed-article:12456031lifeskim:mentionsumls-concept:C1521721lld:lifeskim
pubmed-article:12456031lifeskim:mentionsumls-concept:C0336562lld:lifeskim
pubmed-article:12456031lifeskim:mentionsumls-concept:C1287366lld:lifeskim
pubmed-article:12456031lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:12456031lifeskim:mentionsumls-concept:C1171411lld:lifeskim
pubmed-article:12456031pubmed:dateCreated2002-11-28lld:pubmed
pubmed-article:12456031pubmed:abstractTextSerum bilirubin levels are commonly used to assess extracorporeal detoxification by liver support systems. We tested the hypothesis that intravenous colloids administered before liver support treatment could confound bilirubin values. Eight cirrhotic patients received an infusion of a 6% hydroxy ethyl starch solution (10 ml/kg, 30 minutes) before detoxification using a liver support system (FPSA). Bilirubin was measured before and 1 hour after infusion, and after FPSA treatment (7 hours). Infusion of hydroxy ethyl starch was associated with a drop in bilirubin values (mean, 18%, range, 1-44%, p=0.03 versus baseline values). Bilirubin levels were further reduced during FPSA treatment (mean, 27%, range, 22-34%; p=0.02 versus pretreatment values). In conclusion, hydroxy ethyl starch solution may decrease bilirubin levels in hyperbilirubinemic cirrhotic patients receiving extracorporeal detoxification. The role of potentially confounding factors in liver support studies is discussed further.lld:pubmed
pubmed-article:12456031pubmed:languageenglld:pubmed
pubmed-article:12456031pubmed:citationSubsetIMlld:pubmed
pubmed-article:12456031pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12456031pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12456031pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12456031pubmed:statusMEDLINElld:pubmed
pubmed-article:12456031pubmed:authorpubmed-author:GanglAAlld:pubmed
pubmed-article:12456031pubmed:authorpubmed-author:BauerEElld:pubmed
pubmed-article:12456031pubmed:authorpubmed-author:KramerLLlld:pubmed
pubmed-article:12456031pubmed:authorpubmed-author:MadlCClld:pubmed
pubmed-article:12456031pubmed:authorpubmed-author:GendoAAlld:pubmed
pubmed-article:12456031pubmed:ownerNLMlld:pubmed
pubmed-article:12456031pubmed:authorsCompleteYlld:pubmed
pubmed-article:12456031pubmed:pagination918-22lld:pubmed
pubmed-article:12456031pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:12456031pubmed:articleTitleInfluence of hydroxy ethyl starch infusion on serum bilirubin levels in cirrhotic patients treated with artificial liver support.lld:pubmed
pubmed-article:12456031pubmed:affiliationludwig.kramer@akh-wien.ac.atlld:pubmed